Ipamorelin vs GHRP-2 vs GHRP-6 is the essential comparison within the growth hormone secretagogue class — three peptides that all activate the ghrelin receptor (GHS-R1a) to stimulate pituitary growth hormone release, but with dramatically different selectivity profiles that determine which additional hormones they elevate, how much appetite stimulation they produce, and which research applications each one fits best. Choosing the wrong GH secretagogue for your specific research question can introduce confounding variables that compromise data interpretation — cortisol elevation from GHRP-2, appetite surges from GHRP-6, or insufficient GH pulse amplitude from ipamorelin at conservative doses.

PSPeptides carries all three compounds — ipamorelin, GHRP-2, and GHRP-6 — as well as the popular CJC-1295/Ipamorelin blend and Ipamorelin Spray. For a broader comparison that includes GHRH analogues (sermorelin, CJC-1295, tesamorelin), see our sermorelin vs CJC-1295 vs ipamorelin guide.

Why GH Secretagogues Matter: The Age-Related GH Decline

Growth hormone secretion from the pituitary declines approximately 14% per decade after age 30 — a progressive decline called somatopause that contributes significantly to the loss of lean muscle mass, accumulation of body fat, reduced bone density, impaired sleep quality, slower tissue repair, and thinning skin that characterize biological aging. By age 60, daily GH secretion may be less than half of what it was at age 25. This decline is not due to pituitary failure — aging pituitary somatotroph cells retain the capacity to release GH when properly stimulated — but rather to reduced hypothalamic stimulation (decreased GHRH signaling) and increased somatostatin tone (the inhibitory signal which actively suppresses GH release from somatotrophs).

GH secretagogues like ipamorelin, GHRP-2, and GHRP-6 address this decline by directly stimulating somatotroph cells through GHS-R1a activation — bypassing the reduced hypothalamic GHRH signaling and overcoming somatostatin inhibition. Published research has confirmed that GH secretagogues can restore pulsatile GH release patterns in older adults that approximate youthful amplitude — making them relevant research tools for studying whether GH restoration reverses age-related changes in body composition, sleep, tissue repair, and other somatopause-associated endpoints. For researchers studying GH in the context of muscle and recovery, our muscle growth guide covers the IGF-1-mediated downstream effects. For the MK-677 (ibutamoren) oral GH secretagogue comparison, see our separate guide.

How Do GH Secretagogues Work?

All three peptides activate the same receptor — GHS-R1a (the ghrelin receptor) — on anterior pituitary somatotroph cells. When GHS-R1a is activated, it triggers a signaling cascade that results in growth hormone release from the pituitary. This is mechanistically distinct from GHRH analogues (sermorelin, CJC-1295), which activate the GHRH receptor — a completely separate receptor on the same pituitary cells. GH secretagogues and GHRH analogues are synergistic because they activate two different pathways that converge on GH release, which is why the CJC-1295/ipamorelin combination produces robust GH pulses approximately 3-5x larger in amplitude than either compound administered alone.

Beyond stimulating GH release, GHS-R1a activation produces several other effects — and this is where the three secretagogues diverge. The ghrelin receptor mediates appetite stimulation (ghrelin is the “hunger hormone”), and it has signaling cross-talk with cortisol, prolactin, and ACTH release pathways. How strongly each secretagogue activates these secondary effects — beyond the primary GH release — defines its selectivity profile and determines which research applications it fits.

Ipamorelin vs GHRP-2 vs GHRP-6: Complete Comparison

Ipamorelin: The Selective Choice

Ipamorelin is a synthetic pentapeptide that is the most selective growth hormone secretagogue available. Published pharmacological data demonstrates that ipamorelin stimulates GH release from the pituitary without significantly elevating cortisol, prolactin, or ACTH at standard research doses. This selectivity is ipamorelin’s defining advantage — it isolates the GH release effect from the stress hormone and appetite confounders that GHRP-2 and GHRP-6 introduce.

The clean GH release profile makes ipamorelin the preferred secretagogue for research protocols where isolating growth hormone effects from stress hormone interference is critically important for data interpretation. If your study measures body composition, sleep quality, tissue repair, or any endpoint that could be confounded by cortisol elevation (which promotes catabolism, disrupts sleep architecture, and impairs wound healing), ipamorelin provides the GH stimulus without the cortisol noise. This selectivity is why ipamorelin is the secretagogue component in the CJC-1295/ipamorelin combination — the most popular GH peptide stack in research. Published Phase 2 clinical data has evaluated ipamorelin for postoperative ileus (impaired bowel function after surgery), providing human safety data beyond preclinical models — a level of clinical validation that GHRP-2 and GHRP-6 lack.

The tradeoff is that ipamorelin produces a somewhat smaller GH pulse per dose compared to GHRP-2. For protocols where maximum GH amplitude is the primary endpoint (rather than clean GH isolation), GHRP-2 may be more appropriate despite its cortisol/prolactin activity. PSPeptides offers ipamorelin as a vial, as a nasal spray, and in the CJC-1295/Ipamorelin blend.

GHRP-2: Maximum GH Release

GHRP-2 (pralmorelin) produces the strongest growth hormone release per dose among the three secretagogues — making it the most potent GH stimulator available in the peptide research space. Published pharmacological research has documented robust, dose-dependent GH elevation with GHRP-2, with peak GH levels exceeding those produced by equivalent doses of ipamorelin or GHRP-6.

The tradeoff for this potency is reduced selectivity. At higher doses, GHRP-2 elevates cortisol and prolactin — stress and reproductive hormones that can confound research endpoints. Cortisol elevation promotes protein catabolism and fat storage (opposing the anabolic effects of GH), disrupts sleep architecture, and suppresses immune function. Prolactin elevation can affect reproductive hormone signaling. These off-target effects are dose-dependent — lower GHRP-2 doses produce cleaner GH release with minimal cortisol/prolactin elevation, while higher doses progressively engage these secondary pathways.

GHRP-2 is the best choice for research specifically studying maximum GH pulse amplitude, GH secretory capacity testing, or protocols where the highest possible GH elevation is the primary endpoint and cortisol/prolactin elevation is either acceptable or can be separately measured and controlled for. PSPeptides carries GHRP-2 as a standalone vial.

GHRP-6: The Appetite-Stimulating Secretagogue

GHRP-6 is a synthetic hexapeptide that occupies a unique position among GH secretagogues because of its pronounced appetite-stimulating effect. While all GHS-R1a agonists have some appetite-modulating activity (ghrelin is the body’s primary hunger signal), GHRP-6 produces the strongest, most immediate hunger surge of the three secretagogues — a sharp increase in appetite that typically begins within 20-30 minutes of administration and persists for 30-60 minutes.

This appetite effect is driven by GHRP-6’s strong activation of ghrelin-mediated feeding circuits in the hypothalamic arcuate nucleus — the same pathway that endogenous ghrelin uses to signal hunger. For researchers studying appetite regulation, ghrelin biology, or the intersection of GH release and feeding behavior, GHRP-6’s pronounced appetite stimulation is a feature rather than a side effect — it provides a pharmacological tool for reproducibly activating the ghrelin-mediated hunger pathway.

GHRP-6 also elevates cortisol and prolactin, though generally to a lesser degree than GHRP-2 at equivalent GH-stimulating doses. The appetite stimulation itself follows a predictable temporal pattern: onset within 20-30 minutes of administration, peak hunger at 30-45 minutes, and gradual resolution over the following 30-60 minutes. This predictable timing allows researchers to design protocols that account for the appetite surge — for example, administering GHRP-6 before a planned meal to study the interaction between pharmacological ghrelin activation and normal postprandial metabolic responses. For researchers who want GH secretagogue effects without appetite stimulation, ipamorelin produces minimal hunger — making it the practical choice for protocols where caloric intake is a controlled variable. The appetite distinction between ipamorelin and GHRP-6 is the single most practically relevant difference for most research applications, determining whether the protocol can maintain controlled feeding conditions or must accommodate uncontrolled hunger surges. Its GH release potency is moderate — stronger than ipamorelin at equivalent doses but weaker than GHRP-2. PSPeptides carries GHRP-6 as a standalone lyophilized vial for reconstitution with bacteriostatic water. For researchers who want GH secretagogue effects without the appetite surge, ipamorelin is the clear alternative — its minimal appetite stimulation makes it practical for protocols where uncontrolled food intake would confound body composition or metabolic endpoints.

Choosing the Right Secretagogue by Research Goal

Body composition and fat loss research: Ipamorelin — clean GH release without the cortisol (catabolic) or appetite (caloric surplus) confounders that would oppose the body composition improvements GH promotes. Combine with CJC-1295 (no DAC) for synergistic pulsatile GH release. See our muscle growth guide.

Maximum GH secretory capacity testing: GHRP-2 — strongest GH pulse per dose for research quantifying pituitary secretory reserve. The cortisol/prolactin elevation is an acceptable tradeoff when the endpoint is peak GH amplitude rather than downstream body composition effects.

Appetite and ghrelin biology research: GHRP-6 — the most pronounced appetite-stimulating effect, providing a reliable pharmacological tool for activating ghrelin-mediated feeding circuits. Useful for studies on hunger signaling, meal timing, and the GH-appetite intersection.

Sleep and recovery research: Ipamorelin — evening administration capitalizes on the natural nocturnal GH pulse without the cortisol elevation that would disrupt sleep architecture. See our sleep and recovery guide.

GH + GHRH synergy protocols: Ipamorelin + CJC-1295 (no DAC) — the gold standard combination. Dual receptor activation (GHS-R1a + GHRH-R) produces synergistic GH pulses while ipamorelin’s selectivity keeps the hormonal profile clean. GHRP-2 can substitute for ipamorelin in this stack when maximum GH amplitude outweighs selectivity concerns. See our full GH peptide comparison.

Desensitization and Cycling Considerations

A practical concern with chronic GH secretagogue use is receptor desensitization — the reduction in GH response that can occur with continuous GHS-R1a stimulation. Published research suggests that pulsatile dosing (once or twice daily rather than continuous infusion) better preserves receptor sensitivity than sustained stimulation. All three secretagogues have relatively short half-lives (15 minutes to 2 hours), which naturally produces pulsatile GH release patterns that mimic normal physiology — this is an advantage over longer-acting GH peptides that produce sustained elevation and may accelerate desensitization.

Some researchers incorporate cycling protocols — 5 days on / 2 days off, or 3 weeks on / 1 week off — to prevent receptor downregulation during extended studies. Published data on optimal cycling patterns for GH secretagogues is limited, and protocols vary by researcher preference. Our cycling guide covers the general principles of peptide cycling and how different compound classes (GH secretagogues, tissue repair peptides, longevity peptides) have different cycling requirements based on their receptor pharmacology and tolerance profiles.

Reconstitution and Protocols

All three secretagogues are supplied as lyophilized powder requiring reconstitution with bacteriostatic water. See our reconstitution guide and dosage calculator. Storage at 2-8°C after reconstitution per our storage guide.

Administration timing matters for GH secretagogues because growth hormone release follows circadian patterns. The largest natural GH pulse occurs during slow-wave sleep — typically within the first 90 minutes of sleep onset. Evening administration of GH secretagogues (30-60 minutes before sleep on an empty stomach) amplifies this natural nocturnal pulse, which is why most research protocols use pre-sleep dosing. An empty stomach is important because elevated blood glucose and insulin suppress GH release — eating within 1-2 hours before GH secretagogue administration can significantly blunt the GH response. For GHRP-6 specifically, the appetite surge it produces means researchers should plan for the hunger response that follows administration, especially if pre-sleep dosing is used.

For multi-secretagogue stacking protocols, the most evidence-supported combination is ipamorelin + CJC-1295 (no DAC) — combining a GHRP (ghrelin receptor agonist) with a GHRH analogue (GHRH receptor agonist) for dual-pathway synergistic GH release. GHRP-2 can substitute for ipamorelin in this stack when maximum GH amplitude is prioritized over hormonal selectivity. GHRP-6 is less commonly used in stacks because its appetite stimulation adds a practical complication (intense hunger at bedtime) without proportional GH benefit compared to ipamorelin or GHRP-2. PSPeptides carries the pre-made CJC-1295/Ipamorelin blend for researchers who want the stack in a single vial, and the CJC/Ipamorelin Spray for the nasal format.

Understanding the Downstream Effects of GH Release

All three secretagogues ultimately produce the same downstream effect — growth hormone release from the pituitary — but understanding what GH does once released helps researchers choose appropriate endpoints and protocol durations.

GH stimulates hepatic production of IGF-1 (insulin-like growth factor 1), which mediates most of GH’s anabolic effects on peripheral tissues. IGF-1 promotes muscle protein synthesis, bone mineralization, tendon collagen production, and adipocyte lipolysis. GH also has direct effects on fat metabolism through activation of hormone-sensitive lipase, and on sleep architecture through enhancement of slow-wave sleep duration and quality.

The timeline for measurable effects varies by endpoint. Sleep quality improvements may be noticeable within days. Body composition changes (reduced fat mass, increased lean mass) typically require 4-12 weeks of consistent protocol adherence. Skin and hair quality changes may take 8-16 weeks. Tissue healing acceleration (tendon, ligament) may be measurable within 2-4 weeks with appropriate injury models. Researchers should design protocol duration based on the specific endpoint rather than applying a one-size-fits-all timeline. For more on GH effects, see our muscle growth and recovery guide and our sleep and recovery guide.

Understanding ipamorelin vs ghrp-2 vs ghrp-6 is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

Which GH secretagogue is the most selective?

Ipamorelin — by a significant margin. Published pharmacological data confirms that ipamorelin releases growth hormone without significantly elevating cortisol, prolactin, or ACTH at standard research doses. This hormonal selectivity makes ipamorelin the cleanest GH research tool available — isolating the growth hormone signal from the stress hormone confounders that GHRP-2 and GHRP-6 introduce. For research where cortisol elevation would compromise the study endpoint (body composition, sleep quality, tissue repair, immune function), ipamorelin is the only appropriate secretagogue choice.

Which GH secretagogue produces the strongest GH release?

GHRP-2 — it produces the largest peak GH pulse per dose among the three secretagogues in published pharmacological comparison studies. However, this maximum potency comes with dose-dependent cortisol and prolactin elevation that can confound downstream research endpoints. The choice between maximum GH amplitude (GHRP-2) and clean hormonal selectivity (ipamorelin) depends on whether the research prioritizes peak GH concentration or the purity of the GH signal relative to other hormonal changes.

Why does GHRP-6 cause such strong appetite stimulation?

GHRP-6 strongly activates ghrelin-mediated feeding circuits in the hypothalamic arcuate nucleus — the same pathway that endogenous ghrelin uses to signal hunger. While all GH secretagogues have some appetite activity, GHRP-6’s is the most pronounced, producing a sharp hunger surge within 20-30 minutes of administration.

Can I combine GH secretagogues with GHRH analogues?

Yes — this is the basis of the popular CJC-1295/ipamorelin combination. GH secretagogues (GHS-R1a) and GHRH analogues (GHRH-R) activate different receptors that synergistically produce GH pulses 3-5x larger than either compound alone. Ipamorelin is the preferred secretagogue for this combination due to its selectivity.

All PSPeptides products are sold exclusively for research and laboratory use.